Global autotransfusion systems market is estimated to grow at a CAGR of 5.6% during the forecast period. The rising prevalence of cardiovascular diseases (CVD) is primarily encouraging the demand for the autotransfusion systems market. For instance, the American Heart Association released Heart and Stroke Statistics 2022 unveiling that cardiac arrest remains a public health crisis. There are more than 356,000 out-of-hospital cardiac arrests (OHCA) annually in the US nearly 90% of them fatal. This, in turn, encourages the demand for cardiac surgeries to manage patients’ conditions more effectively.
Browse the full report description of “Autotransfusion Systems Market Size, Share & Trends Analysis Report, By Application (Orthopedic Surgery, Cardiac Surgery, Trauma Procedures, Organ Transplantation, and Other Procedures), By Type (Autotransfusion Products and Accessories) Forecast Period (2022-2030)” at https://www.omrglobal.com/industry-reports/autotransfusion-systems-market
In addition, the market players are contributing to the market growth by adopting numerous strategies such as partnership, collaboration, funding, and regulatory approval, which in turn drives the market growth.
• In August 2022, the US Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions. Zynteglo is a one-time gene therapy product administered as a single dose. Each dose of Zynteglo is a customized treatment created using the patient’s cells (bone marrow stem cells) that are genetically modified to produce functional beta-globin (a haemoglobin component).
• In March 2023, Haemonetics announced that it received FDA 510(k) clearance for next-generation software for the Cell Saver Elite+ autotransfusion system. Cell Saver Elite+ allows hospitals to recover a patient’s blood in surgical procedures. These procedures have the potential for medium to high blood loss. Procedures with the potential for high blood loss include cardiac, orthopaedic, trauma, transplant, vascular and OBGYN surgeries.
To reduce the consumption of blood components, reduce mortality and morbidity and decrease hospital costs, autologous blood transfusion is expected to be integrated into medical practice. The increasing number of organ transplants is further contributing to the market growth. 42,000+ organ transplants were performed in 2022, and nearly 104,234 men, women, and children are on the national transplant waiting list globally, according to the Health Resources & Services Administration.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Application
o By Type
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- Medtronic plc, Fresenius Kabi AG, Becton, Dickinson & Co., LivaNova PLC, and B. Braun Melsungen AG., and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Autotransfusion Systems Market Report Segment
By Application
By Type
Global Autotransfusion Systems Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/autotransfusion-systems-market